



2nd Immune Effector Cell Therapies in Multiple Myeloma Workshop

May 7-8, 2021 | Westin Boston Seaport District and Virtual

PROGRAM CO-CHAIRS:



Adam Cohen, MD
University of Pennsylvania, USA



Hermann Einsele, MD, FRCP
University Hospital Würzburg,
Germany



Nikhil Munshi, MD
Dana Farber Cancer Institute,
USA

Within a very short period of time, there has been a tremendous advance in development of cellular immunotherapies in multiple myeloma (MM). As we have observed during our event last year, a number of groups have presented their data on CAR T-cell therapy in MM. Although the studies are currently small in size, they are accruing patients very quickly, both in the United States and globally.

These developments have highlighted the need for a focused discussion about the state-of-the-art in immune and cellular therapies. With this in mind, the International Myeloma Society (IMS) is organizing the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop. This two-day meeting will review CAR-T clinical data and promising preclinical leads, gain consensus on issues in management of toxicity, and discuss ongoing and future clinical trials. This year we are also including a session on T cell-engaging bispecific antibody-based approaches.



PRELIMINARY PROGRAM

Friday, May 7, 2021

- 8:00-8:15 am **Introduction and Welcome Remarks**
Adam Cohen, Hermann Einsele, and Nikhil Munshi
- 8:15-8:30 am **How will CAR T and BsAb fit in MM treatment paradigm?**
Kenneth Anderson
-

SESSION 1: UPDATE ON BCMA CAR T CLINICAL DATA (Session Chairs: Jesus Berdeja and Paula Rodriguez-Otero)

- 8:30-8:45 am **Update on ide-cel**
Nikhil Munshi
- 8:45-9:00 am **Update on cilta-cel**
Deepu Madduri
- 9:00-9:15 am **Update on orva-cel**
Sham Mailankody
- 9:15-9:30 am **Update on CT053**
Shaji Kumar
- 9:30-9:45 am **Discussion**
- 9:45-10:15 am **Break**
-

SESSION 2: NEXT GENERATION BCMA CAR PRODUCTS IN THE CLINIC (Session Chairs: William Bensinger and Kwee Yong)

- 10:15-10:30 am **bb21217**
Melissa Alsina
- 10:30-10:45 am **BCMA CAR + gamma secretase inhibition**
Damian Green
- 10:45-11:00 am **P-BCMA-101**
Caitlin Costello
- 11:00-11:15 am **ALLO-715**
Parameswaran Hari
- 11:15-11:30 am **FHVH-BCMA-T cells**
Lekha Mikkilineni
- 11:30-11:45 am **Discussion**
- 11:45-12:30 pm **Lunch**

PRELIMINARY PROGRAM CONTINUED

SESSION 3: C A R T CELL CORRELATIVE ANALYSES

(Session Chairs: Madhav V. Dhodapkar and Nizar Bahlis)

12:30-12:45 pm **Lessons from CD19 experience**

Joseph Fraietta

12:45-1:00 pm **ide-cel correlatives**

Shari Kaiser

1:00-1:15 pm **cilta-cel correlatives**

Enrique Zudaire

1:15-1:30 pm **Penn CART-BCMA correlatives**

Jos Melenhorst

1:30-1:45 pm **Single cell immune profiling after CAR T therapy in MM**

Samir Parekh

1:45-2:00 pm **CITE-seq analysis in MM patients getting CAR T and bispecific Ab therapy**

Paola Neri

2:00-2:15 pm **BCMA loss as escape mechanism**

Leo Rasche

2:15-2:30 pm **BCMA loss as escape mechanism**

Mehmet Samur

2:30-2:50 pm **Discussion**

2:50-3:15 pm **Break**

SESSION 4: TOXICITIES OF IMMUNE CELL THERAPY

(Session Chairs: Sundar Jagannath and David Siegel)

3:15-3:30 pm **CRS management in 2021**

Yi Lin

3:30-3:45 pm **Understanding/managing neurotoxicity**

Jeremy Rees

3:45-4:00 pm **Late cytopenias and infections**

Tom Martin

4:00-4:15 pm **Mitigating CRS from bispecific Abs**

Johannes Düll

4:15-4:30 pm **Discussion**

PRELIMINARY PROGRAM CONTINUED

Saturday, May 8, 2021

- 8:00-8:05 am **Opening Remarks**
Adam Cohen, Hermann Einsele, and Nikhil Munshi
- Debate: CAR T vs Bispecific Abs**
(Moderators: Philippe Moreau and Jesus San Miguel)
- 8:05-8:15 am **CAR T cells are better**
Noopur Raje
- 8:15-8:25 am **Bispecific Ab are better**
Nina Shah
- 8:25-8:30 am **Discussion**
-

SESSION 5: NOVEL CELL THERAPY APPROACHES (Session Chairs: Sagar Lonial and Marc Raab)

- 8:30-8:45 am **MIL-based CAR T cell therapy**
Ivan Borrello
- 8:45-9:00 am **Vaccines to augment cell therapy**
David Avigan
- 9:00-9:15 am **Cord blood derived CAR-NK cells**
Paul Lin
- 9:15-9:30 am **FT576 CAR-NK cells**
Jeff Miller
- 9:30-9:45 am **Discussion**
- 9:45-10:15 am **Break**
-

SESSION 6: BCMA BISPECIFIC Abs/TCE FOR MM (Session Chairs: Suzanne Trudel and Simon Harrison)

- 10:15-10:25 am **AMG 420 and 701**
Hermann Einsele
- 10:25-10:35 am **CC-93269**
Luciano Costa
- 10:35-10:45 am **Teclistamab**
Saad Usmani

PRELIMINARY PROGRAM CONTINUED

- 10:45-10:55 am **REGN5458**
Sundar Jagannath
- 10:55-11:07 am **Discussion**
- 11:07-11:17 am **TNB-383B**
Cesar Rodriguez
- 11:17-11:27 am **PF-06863135**
Alexander Lesokhin
- 11:27-11:37 am **GPRC5D bispecific Ab: Talquetamab**
Ajai Chari
- 11:37-11:47 am **FcRH5 bispecific Ab: Cevostamab**
Adam Cohen
- 11:47-11:57 am **Belantamab mafadotin**
Sagar Lonial
- 11:57-12:10pm **Discussion**
- 12:10-1:00 pm **Lunch**
-

SESSION 7: BEYOND BCMA: ALTERNATIVE CAR AND BsAb TARGETS (Session Chairs: Amrita Krishnan and Krina Patel)

- 1:00-1:15 pm **Combined BCMA and CD19 CAR T cells**
Al Garfall
- 1:15-1:30 pm **Targeting BCMA and TACI**
Marcela Maus
- 1:30-1:45 pm **CD38 CAR T cells**
Tuna Mutis
- 1:45-2:00 pm **GPRC5D CAR T cells**
Eric Smith
- 2:00-2:15 pm **SLAMF7 CAR T cells**
Michael Hudecek
- 2:15-2:30 pm **Combined BCMA and CD19 CAR T cells**
Chengcheng Fu
- 2:30-2:45 pm **Discussion**
- 2:45-3:00 pm **Wrap-up**
Adam Cohen, Hermann Einsele, and Nikhil Munshi

THANK YOU TO OUR SPONSORS



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*



ONCOLOGY



International Myeloma Society
www.myelomasociety.org